Vivus CEO resigns, FMC gains board majority in settlement
This article was originally published in Scrip
Executive Summary
Vivus CEO Leland Wilson and president Peter Tam will resign from the company's board of directors and Mr Wilson will resign as CEO under the terms of a settlement with shareholder First Manhattan Co (FMC) that gives the activist investor majority control of the obesity drug developer's board.